Longboard Pharmaceuticals, Inc.
NASDAQ: LBPH0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Kevin R. Lind
- Employees
- 50
- Headquarters
- La Jolla, United States
- IPO year
- 2021
- Market cap
- $2.3B
- Website
- https://www.longboardpharma.com
Loading LBPH…
Loading profile data…Frequently asked questions about LBPH
What does Longboard Pharmaceuticals, Inc. (LBPH) do?
Longboard Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm committed to advancing innovative treatments for neurological conditions. Its primary drug candidate, LP352, is currently progressing through a Phase 1b/2a clinical trial, aimed at managing seizures associated with developmental and epileptic encephalopathies. The company...
Where does LBPH trade?
Longboard Pharmaceuticals, Inc. (LBPH) trades on the NASDAQ Global Market.
What sector is LBPH in?
Longboard Pharmaceuticals, Inc. (LBPH) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Longboard Pharmaceuticals, Inc.?
Kevin R. Lind is the chief executive officer of Longboard Pharmaceuticals, Inc. (LBPH).
Where is Longboard Pharmaceuticals, Inc. headquartered?
Longboard Pharmaceuticals, Inc. is headquartered in United States.
Does LBPH pay a dividend?
Longboard Pharmaceuticals, Inc. (LBPH) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did LBPH go public?
Longboard Pharmaceuticals, Inc. (LBPH) completed its initial public offering in 2021.